Clinical trial · Interventional
The Role of Tranexamic Acid in Reducing Post Operative Hand Edema After Hand and Wrist Surgery
The Role of Tranexamic Acid in Reducing Post Operative Hand Edema After Hand and Wrist Surgery (THAW): A Prospective, Randomized Controlled, Double-Blinded Pilot Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Hand edema following hand surgery is a common yet devastating side effect that can lead to early stiffness, prolonged rehabilitation and diminished function. These factors can reduce a patient's quality of life; mounting to an overall delay in recovery, return to work and daily activities. Conventional edema therapy includes cryotherapy, external compression, active and passive exercises and various types of massage. However, there is little evidence to suggest these modalities are effective. Tranexamic acid (TXA) is an antifibrinolytic that has been used in surgical disciplines for decades to aid in reducing intraoperative blood loss and consequent transfusions. Recently, the use of TXA for curbing post-operative edema and ecchymosis has shown promising results, however, its use in hand surgery has not been studied.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Distal Radius Fracture | — | UNRESOLVED | — |
| Dupuytren Contracture | Palmar Fibromatosis | ALIAS | 0.90 |
| Hand Injuries and Disorders | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Surgery | Procedure | — | UNRESOLVED |
| Tranexamic acid | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Tranexamic Acid (TXA)
- description
- Patients in the TXA arm will receive 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride before their surgery and 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride 3-6 hours after the first dose on the day of their surgery
- interventionNames
- Drug: Tranexamic acid
- Procedure: Surgery
- type
- PLACEBO_COMPARATOR
- label
- Standard of Care (SOC)
- description
- Patients in the (SOC) arm will receive 50cc of IV Placebo (standard intravenous normal saline fluid - 0.9% sodium chloride) before their surgery and 50cc of IV Placebo (standard intravenous normal saline fluid - 0.9% sodium chloride) 3-6 hours after the first dose on the day of their surgery
- interventionNames
- Procedure: Surgery
Primary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * All patients \>18 years old undergoing distal radius fracture open reduction and internal fixation through a volar approach at St. Joseph's hospital in London, Ontario * All patients \>18 years old undergoing open fasciectomy for Dupuytren's disease at St. Joseph's hospital in London, Ontario Exclusion Criteria: * Revision surgery * Distal radius fractures treated with additive or alternative approaches and fixation to the volar approach * Known history of lymphedema or lymph node dissection on either upper extremity * Known allergic reaction to TXA * Cardiovascular problems (history of myocardial infraction, angina, and atrial fibrillation) * Cerebrovascular conditions (history of previous stroke) * Thromboembolic disorders (history of deep vein thrombosis \[DVT\] or pulmonary embolism \[PE\]), clotting disorders) * Known seizure disorder * Currently on dialysis * Current pregnancy or breastfeeding * Current use of hormone contraception * Unable to read consent and patient surveys related to the study in English
References
Publications (0)
Data not yet available